

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 15, 2011**

---

**Cadence Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-33103**  
(Commission  
File Number)

**41-2142317**  
(IRS Employer  
Identification No.)

**12481 High Bluff Drive, Suite 200  
San Diego, California 92130**  
(Address of principal executive offices, including zip code)

**(858) 436-1400**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On June 15, 2011, Cadence Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders in San Diego, California, at which the stockholders voted on proposals as follows:

**Proposal 1.** The election of Dr. James C. Blair, Mr. Alan D. Frazier and Mr. Christopher J. Twomey as directors for a three-year term expiring at the 2014 Annual Meeting of Stockholders:

<u>Nominee</u>	<u>For</u>	<u>Withheld</u>	<u>Broker Non-Votes</u>
James C. Blair	54,727,801	401,520	6,157,502
Alan D. Frazier	55,096,433	32,888	6,157,502
Christopher J. Twomey	55,096,308	33,013	6,157,502

**Proposal 2.** The approval of a non-binding advisory resolution regarding the compensation of the Company’s named executive officers:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
54,835,638	286,664	7,019	6,157,502

**Proposal 3.** The recommendation, by non-binding advisory vote, of the frequency of stockholder non-binding advisory votes regarding the compensation of the Company’s named executive officers:

<u>3 Years</u>	<u>2 Years</u>	<u>1 Year</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
38,732,591	406,349	15,982,446	7,715	6,157,722

In light of the voting results for Proposal 3, the Company’s Board of Directors has determined to hold a stockholder advisory vote on named executive officer compensation every three years.

**Proposal 4.** The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2011:

<u>For</u>	<u>Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
61,246,946	12,726	27,151	N/A

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CADENCE PHARMACEUTICALS, INC.

By: /s/ William R. LaRue  
William R. LaRue  
Senior Vice President, Chief Financial Officer,  
Treasurer and Assistant Secretary

Date: June 17, 2011